Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Champions Oncology, Inc. (CSBR) AI Forecast

Our AI detected a significant signal for Champions Oncology, Inc.. Create a free account to see the exact price target.

Free account • 30-day free trial

$CSBR Bullish Signal Full forecast available

Champions Oncology, Inc. (CSBR) Stock Forecast 2025


Champions Oncology, Inc. (CSBR) AI Stock Price Forecast & Investment Analysis

Champions Oncology, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Champions Oncology, Inc. (CSBR) - Comprehensive Stock Analysis & Investment Research

Deep dive into Champions Oncology, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on March 3, 2026, 7:03 p.m. (UTC)

Champions Oncology, Inc. Investment Summary

When evaluating whether Champions Oncology, Inc. (CSBR) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Champions Oncology, Inc. (CSBR) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. The company employs approximately 198 people. With a market capitalization of $84 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Champions Oncology, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Champions Oncology, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Champions Oncology, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Champions Oncology, Inc.

Sign Up Free
Corporate Identity

Champions Oncology, Inc. (Stock Symbol: CSBR) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Champions Oncology, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Champions Oncology, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Champions Oncology, Inc....

Unlock Full Company Profile

Get complete details about Champions Oncology, Inc.

Sign Up Free
Revenue & Growth Analysis

Champions Oncology, Inc. generates annual revenues of $58 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Champions Oncology, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Champions Oncology, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Champions Oncology, Inc....

Unlock Financial Analysis

Get complete financial metrics for Champions Oncology, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Champions Oncology, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Champions Oncology, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Champions Oncology, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company shows positive operational efficiency through free cash flow generation of $1 million annually , with year-over-year cash flow growth of 56.0%. Positive free cash flow indicates the business generates more cash than required for operations and capital investments, providing resources for growth initiatives or shareholder returns.

Margin & Pricing Power Analysis

The company maintains a 28.4% gross margin reflecting moderate pricing power typical of many manufacturing, retail, or service businesses. While not exceptionally high, these margins provide adequate room for operating expenses and profit generation. Competitive pressures or cost increases could impact profitability if margins compress.

Operating margin of -55.8% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.

Asset Utilization Efficiency

Asset turnover ratio of 1.59x indicates exceptional efficiency in utilizing company assets to generate revenue. High asset turnover is characteristic of retail, distribution, or service businesses that operate with relatively lean asset bases. This efficiency translates to higher returns on invested capital when combined with reasonable margins.

Financial Strength & Leverage

Current ratio of 1.15 suggests tight liquidity where current assets just cover current liabilities. This may be efficient but leaves limited cushion for unexpected needs.

Champions Oncology, Inc. (CSBR) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Champions Oncology, Inc. stock analysis.

Deep dive into Champions Oncology, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Champions Oncology, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Champions Oncology, Inc.: With a P/E ratio of 33.84, the market highly values future growth prospects.

P/E Ratio 33.84x
P/B Ratio 20.21x
Market Cap $84M
EPS $0.44
Book Value/Share $0.30
Revenue/Share $4.21
FCF/Share $-0.09
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Champions Oncology, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Champions Oncology, Inc.: An ROE of 2.6% indicates room for improvement in shareholder value creation.

ROE 2.6%
ROA 0.7%
ROIC 1.3%
Gross Margin 28.4%
Operating Margin -55.8%
Net Margin -60.8%
EBT Margin 0.6%
Tax Rate 24.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Champions Oncology, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Champions Oncology, Inc.: A current ratio of 1.15 shows adequate liquidity.

Current Ratio 1.15x
Quick Ratio 1.11x
D/E Ratio 0.93x
Financial Leverage 3.64x
Working Capital $1M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Champions Oncology, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Champions Oncology, Inc.: Free cash flow of $1M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $4M
Free Cash Flow $1M
Capital Spending -$3M
OCF Growth YoY 56.0%
FCF Growth YoY -33.4%
FCF/Sales 2.1%
CapEx/Sales 5.8%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Champions Oncology, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Champions Oncology, Inc.: An asset turnover of 1.59x demonstrates efficient asset utilization.

Asset Turnover 1.59x
Receivables Turnover 11.4x
Fixed Assets Turnover 3.6x
Days Sales Outstanding 32 days
Payables Period 43 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Champions Oncology, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Champions Oncology, Inc.: With annual revenue of $58M, Champions Oncology, Inc. represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $58M
Operating Income -$8M
Net Income -$8M
R&D Expense $2M
SG&A Expense $31M
Cost of Goods Sold $28M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 53%
Cash & Short-term Investments 26%
Total Liabilities 73%
Accounts Receivable 26%
Dividend & Shareholder Information
Shares Outstanding 14M
Growth Metrics (YoY)
EPS Growth 5.5%

Latest Champions Oncology, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Champions Oncology, Inc. (CSBR) stock price and investment outlook.

More news available

Sign up free to read all 9 news articles and stay updated on market developments.

Sign Up Free to Read More

Champions Oncology, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Champions Oncology, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Acumen Pharmaceuticals, Inc. ABOS ██% $200M -1.9x 2.2x
Abpro Holdings, Inc. ABP ██% $1M x 0.0x
Arcellx, Inc. ACLX ██% $6.61B -74.1x 16.4x
Alpha Cognition Inc. ACOG ██% $126M x 3.7x
Adaptimmune Therapeutics Plc ADAP ██% $77M -13.2x -11.8x
Adma Biologics, Inc. ADMA ██% $3.94B 26.8x 8.3x
Adaptive Biotechnologies Corp ADPT ██% $2.48B -4.6x 11.3x
Adverum Biotechnologies, Inc. ADVM ██% $95M -1.8x 2.2x
Agenus Inc AGEN ██% $110M -0.5x 32.1x
Agentix Corp. AGTX ██% $2M x 296.8x
Aim Immunotech Inc. AIM ██% $3M -0.5x 0.9x
Aim Immunotech Inc. AIMI ██% $1M x x
Alector, Inc. ALEC ██% $244M -1.2x 8.0x
Aligos Therapeutics, Inc. ALGS ██% $43M -19.2x 0.6x
Allogene Therapeutics, Inc. ALLO ██% $591M -1.4x 1.9x
Alvotech ALVO ██% $1.20B x x
Amgen Inc AMGN ██% $207.82B 27.0x 24.0x
Apogee Therapeutics, Inc. APGE ██% $4.84B -20.5x 4.3x
Aptose Biosciences Inc. APTOF ██% $4M x x
Argenx Se ARGX ██% $45.98B x x
Armata Pharmaceuticals, Inc. ARMP ██% $416M -1.0x 21.7x
Artiva Biotherapeutics, Inc. ARTV ██% $123M x 1.0x
Leonabio, Inc. ATHA ██% $23M -0.2x 0.9x
Atara Biotherapeutics, Inc. ATRA ██% $35M 1.5x 4.8x
Atyr Pharma Inc ATYR ██% $97M -3.6x 1.2x
Aura Biosciences, Inc. AURA ██% $387M -4.9x 2.5x
Autolus Therapeutics Plc AUTL ██% $444M x 1.7x
Anavex Life Sciences Corp. AVXL ██% $408M -17.3x 3.2x
Bioatla, Inc. BCAB ██% $15M -1.1x 27.7x
Biocardia, Inc. BCDA ██% $14M -0.6x 5.5x
Brainstorm Cell Therapeutics Inc. BCLI ██% $8M -4.9x 5.6x
Biocryst Pharmaceuticals Inc BCRX ██% $1.87B -12.1x 55.7x
Black Diamond Therapeutics, Inc. BDTX ██% $147M 6.9x 1.2x
Beam Therapeutics Inc. BEAM ██% $3.01B -12.6x 2.4x
Biogen Inc. BIIB ██% $27.61B 21.4x 1.9x
Biontech Se BNTX ██% $26.97B x x
Cabaletta Bio, Inc. CABA ██% $317M -1.6x 2.3x
Candel Therapeutics, Inc. CADL ██% $281M -4.6x 3.5x
C4 Therapeutics, Inc. CCCC ██% $232M -2.6x 1.5x
Cidara Therapeutics, Inc. CDTX ██% $6.49B -1.0x 15.4x
Creative Medical Technology Holdings, Inc. CELZ ██% $6M -3.4x 1.1x
Cero Therapeutics Holdings, Inc. CERO ██% $800K x -196.2x
Cullinan Therapeutics, Inc. CGEM ██% $945M -4.1x 2.1x
Compugen Ltd CGEN ██% $213M x 2.1x
Cg Oncology, Inc. CGON ██% $4.66B x 6.2x
Cognition Therapeutics Inc CGTX ██% $94M -0.5x 2.6x
Coherus Oncology, Inc. CHRS ██% $247M 1.6x 2.8x
Calidi Biotherapeutics, Inc. CLDI ██% $6M -0.9x 0.8x
Cellectis S.A. CLLS ██% $400M x x
Compass Therapeutics, Inc. CMPX ██% $1.01B -4.8x 4.8x
Mosaic Immunoengineering Inc. CPMV ██% $5M x 19.8x
Caribou Biosciences, Inc. CRBU ██% $142M -1.5x 1.0x
Cardiff Oncology, Inc. CRDF ██% $133M -4.0x 2.9x
Cardiol Therapeutics Inc. CRDL ██% $114M x x
Curis Inc CRIS ██% $14M -0.3x 1.5x
Crispr Therapeutics Ag CRSP ██% $5.83B -12.1x 3.0x
Champions Oncology, Inc. CSBR ██% $84M 33.8x 20.2x
Cel Sci Corp CVM ██% $32M -0.9x 2.9x
Dbv Technologies S.A. DBVT ██% $1.28B -3.3x 24.2x
Dbv Technologies S.A. DBVTF ██% $10K x 0.0x
Ginkgo Bioworks Holdings, Inc. DNA ██% $410M -13.9x 0.8x
Denali Therapeutics Inc. DNLI ██% $3.28B -8.7x 3.2x
Precision Biosciences Inc DTIL ██% $104M -2.2x 6.3x
Dyadic International Inc DYAI ██% $28M -7.3x 10.7x
Editas Medicine, Inc. EDIT ██% $201M -0.8x 14.9x
Elutia Inc. ELUT ██% $47M -1.4x 7.1x
Engene Holdings Inc. ENGN ██% $670M 3.7x 4.0x
Entera Bio Ltd. ENTX ██% $63M 8.5x 4.2x
Enzon Pharmaceuticals, Inc. ENZN ██% $4M x 10.3x
Estrella Immunopharma, Inc. ESLA ██% $48M -3.1x 333.4x
Evaxion A/S EVAX ██% $26M x x
Exelixis, Inc. EXEL ██% $10.77B 13.8x 5.0x
Exozymes Inc. EXOZ ██% $68M x 12.6x
Fate Therapeutics Inc FATE ██% $171M -1.3x 0.8x
4d Molecular Therapeutics, Inc. FDMT ██% $533M -3.0x 1.5x
Fennec Pharmaceuticals Inc. FENC ██% $290M 1758.3x 96.2x
Finch Therapeutics Group, Inc. FNCH ██% $21M -0.1x 1.5x
Futuretech Ii Acquisition Corp. FTII ██% $52M x -0.7x
Futuretech Ii Acquisition Corp. FTIIU ██% $14M x -0.8x
Gilead Sciences, Inc. GILD ██% $186.19B 21.9x 8.2x
Monte Rosa Therapeutics, Inc. GLUE ██% $1.35B 64.6x 5.5x
Genenta Science S.P.A. GNTA ██% $23M x 1.8x
Green Planet Bio Engineering Co. Ltd. GPLB ██% $340K x x
Halozyme Therapeutics, Inc. HALO ██% $8.23B 26.0x 168.5x
Humacyte, Inc. HUMA ██% $215M -3.3x 53.1x
Immunitybio, Inc. IBRX ██% $10.56B -3.6x 90.0x
Inhibikase Therapeutics, Inc. IKT ██% $234M -1.0x 3.2x
Immunocore Holdings Plc IMCR ██% $1.66B x 4.4x
Immatics N.V. IMTX ██% $1.21B x x
Immunovant, Inc. IMVT ██% $5.64B -14.5x 5.7x
In8bio, Inc. INAB ██% $17M x 1.3x
Inhibrx Biosciences, Inc. INBX ██% $1.12B -6.8x 30.5x
Mink Therapeutics, Inc. INKT ██% $51M -1.5x 7.6x
Inmune Bio, Inc. INMB ██% $35M -2.5x 1.4x
Intensity Therapeutics, Inc. INTS ██% $19M -2.2x 2.7x
Iovance Biotherapeutics, Inc. IOVA ██% $1.56B -4.5x 2.2x
Century Therapeutics, Inc. IPSC ██% $196M -0.7x 1.1x
Invivyd, Inc. IVVD ██% $485M -0.4x 5.2x
Jasper Therapeutics, Inc. JSPR ██% $38M -3.2x 3.3x
Kalaris Therapeutics, Inc. KLRS ██% $196M x 4.7x
Klotho Neurosciences, Inc. KLTO ██% $47M x 4.7x
Kodiak Sciences Inc. KOD ██% $1.64B -2.5x 69.1x
Krystal Biotech, Inc. KRYS ██% $7.56B 36.9x 6.2x
Kymera Therapeutics, Inc. KYMR ██% $7.33B -17.8x 4.6x
Kyverna Therapeutics, Inc. KYTX ██% $507M x 3.3x
Ladrx Corp LADX ██% $50K x 0.2x
Lineage Cell Therapeutics, Inc. LCTX ██% $449M -4.7x 20.4x
Lenz Therapeutics, Inc. LENZ ██% $391M -6.7x 2.0x
Liminatus Pharma, Inc. LIMN ██% $10M x x
Lexeo Therapeutics, Inc. LXEO ██% $524M -0.4x 4.3x
Maze Therapeutics, Inc. MAZE ██% $2.19B x 5.8x
Mesoblast Ltd MESO ██% $1.93B x x
Meiragtx Holdings Plc MGTX ██% $608M -3.4x 205.6x
Metagenomi, Inc. MGX ██% $57M x 0.3x
Molecular Partners Ag MOLN ██% $203M x x
Moderna, Inc. MRNA ██% $20.82B -3.2x 2.4x
Neurocrine Biosciences Inc NBIX ██% $13.25B 27.7x 4.1x
Nkgen Biotech, Inc. NKGN ██% $2M -0.1x -0.2x
Neumora Therapeutics, Inc. NMRA ██% $564M -3.9x 4.3x
Novavax Inc NVAX ██% $1.64B 3.7x 43.7x
Ocugen, Inc. OCGN ██% $606M -4.3x 171.5x
Outlook Therapeutics, Inc. OTLK ██% $31M -0.2x 3.0x
Palisade Bio, Inc. PALI ██% $263M -0.2x 81.8x
Passage Bio, Inc. PASG ██% $28M -0.6x 1.5x
Vaxcyte, Inc. PCVX ██% $8.12B -20.4x 3.0x
Biomx Inc. PHGE ██% $7M 1.5x 0.7x
Pluri Inc. PLUR ██% $35M -1.4x 363.8x
Protalix Biotherapeutics, Inc. PLX ██% $225M 41.8x 4.3x
Pharmacyte Biotech, Inc. PMCB ██% $7M 0.3x 0.2x
Prime Medicine, Inc. PRME ██% $791M -1.5x 6.5x
Prokidney Corp. PROK ██% $674M x 0.0x
Qiagen N.V. QGEN ██% $10.57B x 3.0x
Quince Therapeutics, Inc. QNCX ██% $5M -1.7x 4.6x
Qrons Inc. QRON ██% $150K x x
Replimune Group, Inc. REPL ██% $553M -3.8x 2.6x
Repligen Corp RGEN ██% $6.69B 136.9x 3.2x
Regenxbio Inc. RGNX ██% $446M -1.8x 2.8x
Relay Therapeutics, Inc. RLAY ██% $1.70B -2.0x 3.0x
Revolution Medicines, Inc. RVMD ██% $19.73B -11.1x 12.1x
Recursion Pharmaceuticals, Inc. RXRX ██% $1.87B -4.7x 1.7x
Sab Biotherapeutics, Inc. SABS ██% $181M 9.7x 1.1x
Sana Biotechnology, Inc. SANA ██% $1.02B -2.1x 5.2x
Scilex Holding Co SCLX ██% $58M -0.4x 5.5x
Scinai Immunotherapeutics Ltd. SCNI ██% $3M -287.8x 0.4x
Sangamo Therapeutics, Inc SGMO ██% $149M -1.6x 23.9x
Solid Biosciences Inc. SLDB ██% $466M -0.9x 2.1x
Silexion Therapeutics Corp SLXN ██% $5M x 0.7x
Senti Biosciences, Inc. SNTI ██% $24M -1.1x 2.9x
Scholar Rock Holding Corp SRRK ██% $5.00B -18.5x 20.4x
Surrozen, Inc./De SRZN ██% $226M -0.5x 4.8x
Sutro Biopharma, Inc. STRO ██% $335M -1.0x 7.5x
Protara Therapeutics, Inc. TARA ██% $341M -2.1x 2.6x
Tarsus Pharmaceuticals, Inc. TARS ██% $3.28B -12.4x 9.5x
Tc Biopharm (Holdings) Plc TCBPY ██% $150K x 0.1x
Tscan Therapeutics, Inc. TCRX ██% $60M -4.6x 0.4x
Bio-Techne Corp TECH ██% $8.90B 109.7x 4.4x
Tectonic Therapeutic, Inc. TECX ██% $451M -8.9x 1.8x
Instil Bio, Inc. TIL ██% $57M -1.1x 0.5x
Tenaya Therapeutics, Inc. TNYA ██% $122M -2.5x 1.5x
Tourmaline Bio, Inc. TRML ██% $1.23B -3.5x 4.8x
Taysha Gene Therapies, Inc. TSHA ██% $1.25B -3.0x 5.7x
Titan Pharmaceuticals Inc TTNP ██% $6M -0.5x 2.2x
Tevogen Bio Holdings Inc. TVGN ██% $52M x 3835.7x
Twist Bioscience Corp TWST ██% $2.87B -12.6x 6.3x
Voyager Acquisition Corp./Cayman Islands VACH ██% $338M 33.1x 0.0x
Voyager Acquisition Corp./Cayman Islands VACHU ██% $68M 6.7x 0.0x
Valneva Se VALN ██% $963M x x
Vericel Corp VCEL ██% $1.81B 109.3x 5.1x
Vir Biotechnology, Inc. VIR ██% $1.27B -2.0x 1.6x
Vivosim Labs, Inc. VIVS ██% $6M x 1.3x
Vor Biopharma Inc. VOR ██% $641M -0.6x 9.7x
Vaxart, Inc. VXRT ██% $169M -0.9x 6.3x
Voyager Therapeutics, Inc. VYGR ██% $227M 570.6x 1.0x
Windtree Therapeutics Inc /De/ WINT ██% $340K -0.4x 0.1x
X4 Pharmaceuticals, Inc XFOR ██% $284M 6.4x 4.6x
Zeo Scientifix, Inc. ZEOX ██% $19M x 27.6x
Zivo Bioscience, Inc. ZIVO ██% $36M -31.3x 23.6x
Zura Bio Ltd ZURA ██% $628M x 5.8x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Champions Oncology, Inc. Stock Forecast

How accurate are Champions Oncology, Inc. stock predictions?

Our AI model shows a -4% Spearman correlation coefficient for CSBR predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Champions Oncology, Inc. stock price forecasts?

Our analysis considers Champions Oncology, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Champions Oncology, Inc. a good investment in 2025?

Based on our AI analysis, Champions Oncology, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Champions Oncology, Inc. forecasts updated?

Champions Oncology, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

My Portfolio

Investment Dashboard

Loading your portfolio...